MediciNova
MediciNova is a biopharmaceutical company focused on developing novel therapeutics for neurology, respiratory, and liver diseases with unmet medical needs. The company is engaged in clinical development of its product candidates MN-001, MN-166, and MN-221, targeting conditions such as fibrotic diseases, neurological disorders, and respiratory diseases. It collaborates with various pharmaceutical companies and has received regulatory designations like orphan drug status from the FDA. MediciNova aims to build a sustainable biopharmaceutical business through strategic development, partnerships, and commercialization of its differentiated products.
Industries
Nr. of Employees
small (1-50)
MediciNova
San Diego, California, United States, North America
Patents
Methods of reducing plasma level of macrophage migratory inhibitory factor in patients
US-12213966-B2
View Details
Methods of reducing plasma level of macrophage migratory inhibitory factor in patients
US-12213966-B2
View DetailsProducts
MN-001 (tipelukast)
An orally bioavailable small-molecule candidate developed for anti-fibrotic and anti-inflammatory indications; demonstrated multi-mechanistic activity in preclinical models (leukotriene receptor antagonism, PDE3/4 inhibition, 5-LO inhibition) and down-regulation of fibrosis/inflammation-related genes.
MN-166 (ibudilast)
An orally bioavailable small-molecule glial attenuator under development for progressive multiple sclerosis, ALS, and drug-dependence indications; modulates neuroinflammation by suppressing pro-inflammatory cytokines and acting as a functional TLR4 antagonist.
MN-221
A small-molecule candidate in development for acute exacerbations of asthma and COPD exacerbations.
MN-001 (tipelukast)
An orally bioavailable small-molecule candidate developed for anti-fibrotic and anti-inflammatory indications; demonstrated multi-mechanistic activity in preclinical models (leukotriene receptor antagonism, PDE3/4 inhibition, 5-LO inhibition) and down-regulation of fibrosis/inflammation-related genes.
MN-166 (ibudilast)
An orally bioavailable small-molecule glial attenuator under development for progressive multiple sclerosis, ALS, and drug-dependence indications; modulates neuroinflammation by suppressing pro-inflammatory cytokines and acting as a functional TLR4 antagonist.
MN-221
A small-molecule candidate in development for acute exacerbations of asthma and COPD exacerbations.
Services
Engagements to discuss licensing, profit-sharing, co-development or investment opportunities for prioritized and non-prioritized drug candidates.
Management of external collaborations for global development of product candidates, including coordination with co-developers and international partners.
Engagements to discuss licensing, profit-sharing, co-development or investment opportunities for prioritized and non-prioritized drug candidates.
Management of external collaborations for global development of product candidates, including coordination with co-developers and international partners.
Expertise Areas
- Clinical trial management
- Preclinical pharmacology
- Fibrosis therapeutics development
- Neurology drug development
Key Technologies
- Oral small-molecule therapeutics
- Rodent disease models (STAM NASH, bleomycin-induced pulmonary fibrosis)
- Gene expression analysis (mRNA biomarkers)
- Histopathology scoring systems (NAS, Ashcroft)
News & Updates
MediciNova announced it will present data on MN-001 for IPF at ICLAF.
MediciNova announced the initiation of a clinical trial for MN-166 in ALS.
MediciNova received a notice of allowance for a patent covering MN-001 and MN-002 for liver disorders.
MediciNova announced it will present data on MN-001 for IPF at ICLAF.
MediciNova announced the initiation of a clinical trial for MN-166 in ALS.
MediciNova received a notice of allowance for a patent covering MN-001 and MN-002 for liver disorders.